Zydus Lifesciences to acquire French medtech Amplitude Surgical for Rs 2,447 crore

Zydus Lifesciences has been trying to get into allied areas such as MedTech and consumer health.

Zydus Lifesciences has entered into exclusive negotiations to acquire a controlling 85.6 percent stake in France-based Amplitude Surgical SA, a leading medical technology company specialising in lower-limb orthopaedic solutions, the Indian firm said on March 11.

The deal, valued at euro 256.8 million (Rs 2446.5 crore), will see Zydus pay euro 6.25 (around Rs 595) for a share of Amplitude , an 80.6 percent premium over the last closing price.

"We believe this was a natural extension in the field of medical technology,” Zydus managing director Dr Sharvil Patel said.

“In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies.”

After the block acquisition, Zydus will launch a mandatory simplified cash tender offer for the remaining shares at the same price, potentially leading to a full acquisition valued at €300 million and subsequent delisting from Euronext Paris.

The transaction is subject to regulatory approvals, including clearance from France’s ministry of economy. The deal is expected to close in the first half of this year.

The acquisition will help Zydus diversify into medtech, leveraging Amplitude’s market presence, R&D, and global distribution network.

Zydus has been trying to expand beyond its branded generics business into allied areas like MedTech and consumer health.

Founded in 1997, the French firm clocked a revenue of euro 106 million in FY24, with operations spanning Europe, Brazil, Australia, and South Africa. The company's surgical implants are gaining ground worldwide.

Amplitude provides numerous value-added innovations to meet the needs of patients, surgeons
and healthcare facilities. These include the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints.

Supported by PAI Partners, through its Mid-Market Fund, Amplitude Surgical has seen significant growth over the past four years, driven by new product development, international growth, investments in manufacturing capabilities and R&D.